
Sign up to save your podcasts
Or
This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor.
In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with Zain Ul Abideen Asad MD, discuss this ACC.22 Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy.
3.8
4747 ratings
This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor.
In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with Zain Ul Abideen Asad MD, discuss this ACC.22 Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy.
130 Listeners
319 Listeners
160 Listeners
862 Listeners
494 Listeners
22 Listeners
32 Listeners
87 Listeners
135 Listeners
1,082 Listeners
39 Listeners
186 Listeners
415 Listeners
35 Listeners
135 Listeners